AMAG Pharmaceuticals.

Additionally, AMAG plans to initiate a wide global registrational plan for Feraheme for the treating IDA of the underlying trigger in mid-2010 regardless. Supply AMAG Pharmaceuticals, Inc.. AMAG Pharmaceuticals, Takeda Pharmaceutical announce Feraheme collaboration AMAG Pharmaceuticals, Inc. AMAG receives a $60 million upfront payment and is usually eligible to receive up to $220 million in development and commercial milestones. Additionally, AMAG shall receive tiered, double-digit royalties based on net product sales of Feraheme in the certified territories. AMAG shall execute and fund the global scientific development of Feraheme in every potential therapeutic indications.Integrated features include ‘one-click’ access to individual patient charts, the capability to simultaneously view multiple charts, to track the complete patient treatment knowledge at a single glance, and alerts that notify the clinician of overdue treatment moments, medication conflicts and conflicting orders. Furthermore to providing the primary Electronic Health Record to its physicians, WPAHS will provide view-only access to key elements of the Electronic Health Record for all utilized caregivers in the system’s hospitals.